Genscript Biotech Corporation (G51) — Net Asset Quality Index
Genscript Biotech Corporation (G51) has a Net Asset Quality Index of 81.7% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €4.85 Billion minus total liabilities of €888.59 Million yields net assets of €3.96 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check asset resilience ratio of Genscript Biotech Corporation to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Genscript Biotech Corporation Net Asset Quality Index Over Time (2016–2025)
This chart shows how Genscript Biotech Corporation's Net Asset Quality Index has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the index stands at 81.7%, representing net assets of €3.96 Billion against total assets of €4.85 Billion EUR. See G51 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Genscript Biotech Corporation (2016–2025)
The table below presents the year-by-year Net Asset Quality Index for Genscript Biotech Corporation from 2016 to 2025, covering 10 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see G51 market cap overview.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 81.7% | €3.96 Billion | €4.85 Billion | €888.59 Million | ▼ -0.2 pp |
| 2024 | 81.9% | €4.32 Billion | €5.28 Billion | €954.91 Million | ▲ +21.6 pp |
| 2023 | 60.4% | €2.04 Billion | €3.39 Billion | €1.34 Billion | ▲ +6.8 pp |
| 2022 | 53.5% | €1.36 Billion | €2.55 Billion | €1.18 Billion | ▲ +4.6 pp |
| 2021 | 49.0% | €1.09 Billion | €2.23 Billion | €1.14 Billion | ▼ -7.4 pp |
| 2020 | 56.3% | €815.59 Million | €1.45 Billion | €631.82 Million | ▲ +14.5 pp |
| 2019 | 41.9% | €372.30 Million | €889.41 Million | €517.11 Million | ▼ -11.9 pp |
| 2018 | 53.8% | €493.30 Million | €916.98 Million | €423.68 Million | ▲ +8.5 pp |
| 2017 | 45.3% | €228.32 Million | €504.26 Million | €275.94 Million | ▼ -36.1 pp |
| 2016 | 81.4% | €184.02 Million | €226.03 Million | €42.01 Million | — |